Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Atrial Fibrillation | Treatment Algorithms | Claims Data Analysis | US | 2014
For the estimated 4.6 million people in the United States who suffer from atrial fibrillation (AF), several treatment approaches and a wide range of pharmacological treatment options are available…
TreatmentTrends: Hepatitis C | Treatment Algorithms | Claims Data Analysis | US | 2014
Hepatitis C virus (HCV) chronic infection is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The FDA’s approval of Gilead…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Brazil for Breast Cancer, NSCLC, CRC, and Malignant Melanoma | Physician & Payer Forum | Brazil and Mexico | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into…
Hepatitis C Virus (How Will All-Oral, Interferon-Free Antiviral Regimens Influence Physician and Payer Attitudes Toward Treatment and Reimbursement in the Cost-Constrained EU5?) | Physician & Payer Forum | EU5 | 2014
In January 2014, the European Medicines Agency granted marketing authorization to the first nucleotide polymerase inhibitor, sofosbuvir (Gilead’s Sovaldi), for the treatment of hepatitis C virus…
Oncology (Securing Favorable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker-Driven Prescribing in Oncology) | Physician & Payer Forum | EU5 | 2014
As oncology increasingly moves toward personalized approaches to therapy, the use of predictive biomarkers will become more important. A plethora of biomarker-driven brands are already available…
